The United Kingdom and the United States have agreed to a significant trade agreement that will guarantee no levies on British medicine shipments being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge secures that tariffs on these crucial exports will stay at nothing for a timeframe of 36 months.
This development is in response to recent statements to hike import taxes on patented pharmaceutical products, with increases floated up to double the cost.
"This agreement with the United Kingdom strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic medicine commerce," a statement noted.
Commercial Significance
Drugs are one of the UK's most significant export categories to the United States, which is easily the largest market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This value represented 17.4% of British export trade in that period.
"This guarantee secures jobs, stimulates funding and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official commented.
Key NHS Changes
The pact includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. In the past, repayments topped twenty percent.
Industry Background
The pact follows a ongoing row between the sector and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by arguments that US customers were charged several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward American operations.
One official publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
